NeuroOne Medical Technologies Corporation NMTC 深 沪
等待开盘 12-20 09:30:00 美东时间
0.7334
+0.017
+2.42%
华盛通- 最 高0.8259
- 今 开0.7269
- 成交量 34.28万股
- 最 低 0.5456
- 昨 收 0.7161
- 总市值 1187.63万
- 52周最高 1.39
- 市盈率 静 --
- 换手率 2.12%
- 52周最低 0.3954
- 委 比 -66.67%
- 总股本 1619.35万
- 历史最高 7.97
- 量 比 1.13
- 振 幅 39.14%
- 历史最低 0.3954
- 每 手 1
- 风险率 0.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne announced Clara, a patient treated with its OneRF® Ablation System, has been seizure-free for over a year. The system, FDA-cleared for diagnostic and therapeutic use, helped Clara regain her life after experiencing up to 10 seizures daily. NeuroOne plans to expand the technology for other applications, including treating facial pain.
06-23 12:30
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary
NeuroOne Medical Technologies has appointed Emily Johns as General Counsel and Corporate Secretary, enhancing its management team and expected to lower legal costs. Johns, an experienced lawyer, joins after nearly a decade of collaboration, bringing expertise in navigating fast-growing companies. She received a stock option grant of 500,000 shares as part of her employment inducement.
06-03 12:30
NeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025
NeuroOne Medical Technologies will participate in the MedInvest MedTech, AI & Digital Health Conference in San Francisco on June 3-4, 2025. CEO Dave Rosa will engage with investors and discuss the company's innovative solutions for neurological disorders and its potential in AI applications.
05-29 17:05
NeuroOne Medical Technologies Accelerates Anticipated Timeline Of 510(k) Submission To FDA For OneRF Trigeminal Nerve Ablation System
Submission for New Intended Use That Leverages Company's Patented OneRF® Technology Platform Expected in May 2025
03-11 21:01
